| MDL | - |
|---|---|
| Molecular Weight | 460.50 |
| Molecular Formula | C26H25FN4O3 |
| SMILES | FC1=CC=C(N2N=CC3=CC(O[C@@H]([C@@H](NC(C4CC4)=O)C)C5=CC=C(N=C5)OC)=CC=C23)C=C1 |
AZD2906 is a selective glucocorticoid receptor (GR) agonist, increases micronucleated immature erythrocytes in the bone marrow of rats. AZD2906 shows IC 50 s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively [1] .
IC50: 2.2 nM (Glucocorticoid receptor, Human PBMC), 0.3 nM (Glucocorticoid receptor, Rat PBMC), 41.6 nM (Glucocorticoid receptor, Human whole blood), 7.5 nM (Glucocorticoid receptor, Rat whole blood) [1]
AZD2906 is a selective glucocorticoid receptor (GR), with IC 50 s of 2.2, 0.3, 41.6 and 7.5 nM at GR in human, rat PBMC and human, rat whole blood, respectively [1] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
AZD2906 (5, 25, 50 mg/kg, p.o.) increases micronucleated immature erythrocytes (MIE) in the bone marrow of rats after treatment for 2 days
[1]
.
AZD2906 (5, 25 mg/kg, p.o.) induces an accumulation of glycogen in the liver of rats, and exhibits cortical lymphocytic atrophy of a moderate to marked degree in the thymus of rats
[1]
.
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
| Animal Model: | Male Wistar Han rats (10 weeks old) [1] |
| Dosage: | 5, 25, 50 mg/kg |
| Administration: | P.O. for 2 days |
| Result: | Caused significant increase in micronucleated immature erythrocytes (MIE) at all doses after analysis of the standard 2000 IE. |
Solid
Room temperature in continental US; may vary elsewhere.
| Powder | -20°C | 3 years |
|---|---|---|
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
DMSO : 125 mg/mL ( 271.44 mM ; Need ultrasonic)
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.1716 mL | 10.8578 mL | 21.7155 mL |
| 5 mM | 0.4343 mL | 2.1716 mL | 4.3431 mL |
| 10 mM | 0.2172 mL | 1.0858 mL | 2.1716 mL |